• Pfizer's Xalkori makes it onto Cancer Drugs Fund pharmatimes
    July 06, 2018
    NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung cancer is made available via the Cancer Drugs Fund (CDF).
PharmaSources Customer Service